Sen. Grassley Wants "Independent" Drug Safety Function In FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee chairman urges structural change at FDA during hearing on Merck's withdrawn COX-2 inhibitor Vioxx. Ranking Democrat Baucus says idea "makes sense;" FDA's Kweder tells the committee she personally has no objection to an independent safety office.